Deutsche Bank Ag\ Tango Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 36,653 shares of TNGX stock, worth $90,532. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,653

Previous 29,525 24.14%

Holding current value

$90,532

Previous $227,000 50.22%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.79 - $7.46 $19,887 - $53,174	7,128 Added 24.14%	36,653 $113,000
Q3 2024 Nov 13, 2024	BUY	$7.36 - $11.93 $51,704 - $83,808	7,025 Added 31.22%	29,525 $227,000
Q2 2024 Aug 14, 2024	BUY	$6.66 - $10.15 $14,365 - $21,893	2,157 Added 10.6%	22,500 $193,000
Q1 2024 May 15, 2024	SELL	$7.51 - $12.88 $32,187 - $55,203	-4,286 Reduced 17.4%	20,343 $161,000
Q4 2023 Feb 14, 2024	SELL	$6.52 - $12.01 $3,651 - $6,725	-560 Reduced 2.22%	24,629 $243,000
Q3 2023 Nov 09, 2023	SELL	$2.93 - $11.26 $506 - $1,947	-173 Reduced 0.68%	25,189 $283,000
Q2 2023 Aug 14, 2023	SELL	$2.67 - $4.7 $22,951 - $40,401	-8,596 Reduced 25.31%	25,362 $84,000
Q1 2023 May 15, 2023	BUY	$3.76 - $8.06 $36,810 - $78,907	9,790 Added 40.51%	33,958 $134,000
Q4 2022 Feb 13, 2023	BUY	$3.41 - $8.29 $17,837 - $43,364	5,231 Added 27.62%	24,168 $175,000
Q3 2022 Nov 14, 2022	SELL	$3.25 - $5.46 $10,114 - $16,991	-3,112 Reduced 14.11%	18,937 $69,000
Q2 2022 Aug 11, 2022	BUY	$3.86 - $8.01 $85,109 - $176,612	22,049 New	22,049 $100,000

Others Institutions Holding TNGX

# of Institutions

135

Shares Held

92.6M

Call Options Held

3.1K

Put Options Held

1.5K

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $218M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account